November 3, 2021 -- Astellas Venture Management, a subsidiary of Astellas Pharma, and LabCentral announced that Thymmune Therapeutics and M13 Therapeutics are the winners of the Future Innovator Prize.
The prize, which is sponsored by Astellas, is offered to entrepreneurial scientists or emerging biotechnology startups. The winners receive one year of use at LabCentral's lab facility in Cambridge, MA, and access to Astellas' R&D capabilities and business leaders.
Thymmune Therapeutics is applying its proprietary thymic engineering platform to develop and commercialize cell therapy products. M13 Therapeutics is working to overcome the limitations of current gene therapies by harnessing phage-derived particles.
Copyright © 2021 scienceboard.net
Member Rewards
Earn points for contributing to market research. Redeem your points for merchandise, travel, or even to help your favorite charity.
Research Topics
Interact with an engaged, global community of your peers who come together to discuss their work and opportunities.
Conferences
Connect
